Lexington, Mass. – Voyager Therapeutics, a leading biotechnology company, has announced a collaboration and license agreement with pharmaceutical giant Novartis. This deal, potentially worth over $1 billion, marks an exciting development for both companies.
Under the agreement, Voyager will provide Novartis with a target-exclusive license to its Tracer capsids and other intellectual property. Together, the companies will focus on developing gene therapies for Huntington’s disease and spinal muscular atrophy.
In exchange, Voyager will receive substantial upfront consideration, including $100 million in cash and a $20 million purchase of newly issued equity from Novartis. Additionally, Voyager stands to gain up to $1.2 billion in preclinical, development, regulatory, and sales milestones, along with royalties on product sales resulting from the collaboration.
According to a filing with the U.S. Securities and Exchange Commission, Novartis plans to acquire approximately 2.15 million Voyager shares, implying a purchase price of approximately $9.32 per share. This represents a 10% premium compared to Friday’s closing price of $8.44.
With this collaboration, Voyager anticipates an extension of its financial runway into mid-2026. This injection of funds will support the company’s ongoing research and development efforts.
As a result of this exciting news, shares of Voyager Therapeutics have surged by 23% in premarket trading and are currently valued at $10.40.
Leave a Reply